Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China [PDF]
Frontiers in Cellular and Infection MicrobiologyCarbapenem-resistant Acinetobacter baumannii (CRAB) is resistant to almost all antibiotics. Eravacycline, a newer treatment option, has the potential to treat CRAB infections, however, the mechanism by which CRAB isolates develop resistance to ...
Yi-tan Li +10 more
doaj +2 more sources
A Divergent Route to Eravacycline
The Journal of Organic Chemistry, 2017 A convergent route to eravacycline (1) has been developed by employing Michael-Dieckmann cyclization between enone 3 and a fully built and protected left-hand piece (LHP, 2). After construction of the core eravacycline structure, a deprotection reaction was developed, allowing for the isoxazole ring opening and global deprotection to be achieved in one
Wu-Yan Zhang +4 more
openaire +3 more sources
Eravacycline for the treatment of intra-abdominal infections
Expert Opinion on Investigational Drugs, 2014 There has been a dramatic increase in the incidence of multidrug-resistant pathogens over the past few years, which highlights the need for new anti-infective therapeutics. Eravacycline is a novel, broad-spectrum synthetic tetracycline indicated for the treatment of severe infections caused by Gram-positive and Gram-negative bacteria.In this review ...
Bassetti M., Righi E.
core +6 more sources
Journal of Global Antimicrobial ResistanceObjectives: Eravacycline, a new tetracycline derivative, exhibits broad-spectrum antimicrobial susceptibility. This study aimed to comprehensively investigate in vitro activities of eravacycline, tigecycline, and ertapenem against various Gram-positive ...
Ming-Han Tsai +2 more
exaly +3 more sources
Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistant Acinetobacter baumannii infections (intracranial, pulmonary, and bloodstream) in a post-trauma adolescent female: a case report [PDF]
Frontiers in MedicineBackgroundCarbapenem-resistant Acinetobacter baumannii (CRAB) is a leading cause of hospital-acquired infection among critically ill patients, with extremely limited therapeutic options, particularly for central nervous system (CNS) infections ...
Jieluan Lu +3 more
doaj +2 more sources
Real-World Experience on the Use of Eravacycline at Doses of 1 mg/kg Bodyweight and Fixed Dose Strategy in Two European Tertiary Centers [PDF]
AntibioticsBackground: Eravaycline is a novel fully synthetic fluorocycline that is currently approved for complicated intra-abdominal infections. However, it is sometimes also used off-label in tertiary care centers for other infection sites as an antibiotic of ...
Karin Oberreiter +8 more
doaj +2 more sources
Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease [PDF]
Microbiology SpectrumTreatment of Mycobacterium abscessus (MAB) pulmonary diseases is challenging due to intrinsic resistance to many antibiotics and requires prolonged intravenous therapy with drugs that have severe side effects.
Sanjay Singh +6 more
doaj +2 more sources
Journal of Infection and Public HealthBackground: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a substantial healthcare challenge. This study assessed the in vitro efficacy of selected antibiotic combinations against CRKP infections.
Yu-Shan Huang +6 more
doaj +2 more sources
Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent Klebsiella pneumoniae in mouse models [PDF]
Antimicrobial Agents and ChemotherapyCarbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) presents a major challenge for clinical treatment due to its characteristics of drug resistance and hypervirulence.
Ruyi Zhang +7 more
doaj +2 more sources
AntibioticsBackground: Eravacycline exhibits potent activity against multidrug-resistant pathogens and holds promise for the management of hospital-acquired and ventilator-associated pneumonia (HAP/VAP).
Jingjing He +8 more
doaj +2 more sources